La dialisi peritoneale: una metodica ''a termine'' a causa della peritonite sclerosante incapsulante?

Translated title of the contribution: [Peritoneal dialysis: a time-limited therapy because of encapsulating peritoneal sclerosis?].

Silvio V. Bertoli, Claudio Musetti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Encapsulating peritoneal sclerosis (EPS) is a rare but severe disease with a mortality rate of 24%-54%, whose main risk factor is peritoneal dialysis (PD) (cumulative incidence 0.5%-7.3%). Although the role of the time spent on peritoneal dialysis is not completely clear, the available evidence suggests that peritoneal dialysis should not be discontinued early for the sake of reducing the EPS risk. We proposed a ''pro-con'' debate which confirmed that PD is not a time-limited technique. Nevertheless, in patients on long-term PD, surveillance of the peritoneal membrane is crucial. The development of EPS requires two ''hits'': first a chronic, inflammatory stimulus, which is typical of peritoneal dialysis, then a second event like PD interruption or kidney transplant. The main pharmacological and dialysis strategies that have been used as primary prevention did not show any significant results, and benefits are more likely to be achieved by reducing the peritoneal inflammation and better preservation of the membrane integrity, for example by means of more biocompatible PD solutions. Among the main surveillance and early diagnosis procedures other than the peritoneal equilibration test, the Ca-125 appearance rate and new tests that evaluate the peritoneal water transport seem to be promising.

Original languageItalian
Pages (from-to)464-468
Number of pages5
JournalGiornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
Volume27
Issue number5
Publication statusPublished - Sep 2010

Fingerprint

Peritoneal Fibrosis
Peritoneal Dialysis
Therapeutics
Membranes
Dialysis Solutions
Primary Prevention
Rare Diseases
Early Diagnosis
Dialysis
Pharmacology
Inflammation
Transplants
Kidney

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{ac4a610643344dcfa2050620b8898d8c,
title = "La dialisi peritoneale: una metodica ''a termine'' a causa della peritonite sclerosante incapsulante?",
abstract = "Encapsulating peritoneal sclerosis (EPS) is a rare but severe disease with a mortality rate of 24{\%}-54{\%}, whose main risk factor is peritoneal dialysis (PD) (cumulative incidence 0.5{\%}-7.3{\%}). Although the role of the time spent on peritoneal dialysis is not completely clear, the available evidence suggests that peritoneal dialysis should not be discontinued early for the sake of reducing the EPS risk. We proposed a ''pro-con'' debate which confirmed that PD is not a time-limited technique. Nevertheless, in patients on long-term PD, surveillance of the peritoneal membrane is crucial. The development of EPS requires two ''hits'': first a chronic, inflammatory stimulus, which is typical of peritoneal dialysis, then a second event like PD interruption or kidney transplant. The main pharmacological and dialysis strategies that have been used as primary prevention did not show any significant results, and benefits are more likely to be achieved by reducing the peritoneal inflammation and better preservation of the membrane integrity, for example by means of more biocompatible PD solutions. Among the main surveillance and early diagnosis procedures other than the peritoneal equilibration test, the Ca-125 appearance rate and new tests that evaluate the peritoneal water transport seem to be promising.",
author = "Bertoli, {Silvio V.} and Claudio Musetti",
year = "2010",
month = "9",
language = "Italian",
volume = "27",
pages = "464--468",
journal = "Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia",
issn = "0393-5590",
publisher = "Wichtig Publishing Srl",
number = "5",

}

TY - JOUR

T1 - La dialisi peritoneale

T2 - una metodica ''a termine'' a causa della peritonite sclerosante incapsulante?

AU - Bertoli, Silvio V.

AU - Musetti, Claudio

PY - 2010/9

Y1 - 2010/9

N2 - Encapsulating peritoneal sclerosis (EPS) is a rare but severe disease with a mortality rate of 24%-54%, whose main risk factor is peritoneal dialysis (PD) (cumulative incidence 0.5%-7.3%). Although the role of the time spent on peritoneal dialysis is not completely clear, the available evidence suggests that peritoneal dialysis should not be discontinued early for the sake of reducing the EPS risk. We proposed a ''pro-con'' debate which confirmed that PD is not a time-limited technique. Nevertheless, in patients on long-term PD, surveillance of the peritoneal membrane is crucial. The development of EPS requires two ''hits'': first a chronic, inflammatory stimulus, which is typical of peritoneal dialysis, then a second event like PD interruption or kidney transplant. The main pharmacological and dialysis strategies that have been used as primary prevention did not show any significant results, and benefits are more likely to be achieved by reducing the peritoneal inflammation and better preservation of the membrane integrity, for example by means of more biocompatible PD solutions. Among the main surveillance and early diagnosis procedures other than the peritoneal equilibration test, the Ca-125 appearance rate and new tests that evaluate the peritoneal water transport seem to be promising.

AB - Encapsulating peritoneal sclerosis (EPS) is a rare but severe disease with a mortality rate of 24%-54%, whose main risk factor is peritoneal dialysis (PD) (cumulative incidence 0.5%-7.3%). Although the role of the time spent on peritoneal dialysis is not completely clear, the available evidence suggests that peritoneal dialysis should not be discontinued early for the sake of reducing the EPS risk. We proposed a ''pro-con'' debate which confirmed that PD is not a time-limited technique. Nevertheless, in patients on long-term PD, surveillance of the peritoneal membrane is crucial. The development of EPS requires two ''hits'': first a chronic, inflammatory stimulus, which is typical of peritoneal dialysis, then a second event like PD interruption or kidney transplant. The main pharmacological and dialysis strategies that have been used as primary prevention did not show any significant results, and benefits are more likely to be achieved by reducing the peritoneal inflammation and better preservation of the membrane integrity, for example by means of more biocompatible PD solutions. Among the main surveillance and early diagnosis procedures other than the peritoneal equilibration test, the Ca-125 appearance rate and new tests that evaluate the peritoneal water transport seem to be promising.

UR - http://www.scopus.com/inward/record.url?scp=79952111511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952111511&partnerID=8YFLogxK

M3 - Articolo

C2 - 20922677

AN - SCOPUS:79952111511

VL - 27

SP - 464

EP - 468

JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

SN - 0393-5590

IS - 5

ER -